Medical Treatment
Study finds lecanemab clears amyloid but shows no short-term recovery in brain waste-clearance system
በAI የተዘገበ በ AI የተሰራ ምስል እውነት ተፈትሸ
Researchers at Osaka Metropolitan University report that while the Alzheimer’s drug lecanemab reduces amyloid plaques, MRI measures found no improvement in the brain’s glymphatic waste-clearance three months after treatment began, underscoring the disease’s complexity and the need for multi-target approaches.
Servier Egypt has launched Tibsovo (ivosidenib), the first targeted therapy available in the country for patients with IDH1-mutated Acute Myeloid Leukemia (AML) and intrahepatic cholangiocarcinoma. The treatment offers a median overall survival of 29.3 months for eligible AML patients and 10.3 months for those with intrahepatic cholangiocarcinoma, according to clinical data. It is approved as a first-line treatment for AML and a second-line option for intrahepatic cholangiocarcinoma.
በAI የተዘገበ
Judy Wanyoike was diagnosed with stage 2B cervical cancer in 2012 following a Pap Smear test. Despite surgery, chemotherapy, and radiation therapy, the cancer returned in 2019 and again in 2022. Experts stress the need for early detection to prevent recurrence.